Track topics on Twitter Track topics that are important to you
510 Charmany DriveSuite 151
United States of America
A public offering of about 3.7 million units of common stock and common warrants was priced by OpGen at $3.25 each in hopes o -More-
An agreement was reached by OpGen with Thermo Fisher Scientific to allow Thermo Fisher's real-time PCR technology to be used -More-
Stock Monitor: VolitionRx Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 15, 2018 / Active-Investors.com has just released a free research report on OpGen, Inc. (NASDAQ: OPGN). If you want...
Nasdaq notified OpGen that it regained its compliance with applicable listing standards. -More-
GAITHERSBURG, Md., Jan. 17, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announced today that it will implement a 1-for-25 reverse stock split of its common stock. The Company filed an amen...
GAITHERSBURG, Md., Feb. 07, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announces the closing of its previously announced public offering of 2,841,152 units at $3.25 per unit and 851,...
OpGen® Technologies is a leading provider of genetic analysis services and systems. The company's proprietary "Optical Mapping" system (see technology) is used by academic and commercial organization...
We have published hundreds of OpGen, Inc. news stories on BioPortfolio along with dozens of OpGen, Inc. Clinical Trials and PubMed Articles about OpGen, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of OpGen, Inc. Companies in our database. You can also find out about relevant OpGen, Inc. Drugs and Medications on this site too.
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...